Proteomic profiling of pancreatic cancer for biomarker discovery.
Pancreatic cancer is a uniformly lethal disease that is difficult to diagnose at early stage and even more difficult to cure. In recent years, there has been a substantial interest in applying proteomics technologies to identify protein biomarkers for early detection of cancer. Quantitative proteomic profiling of body fluids, tissues, or other biological samples to identify differentially expressed proteins represents a very promising approach for improving the outcome of this disease. Proteins associated with pancreatic cancer identified through proteomic profiling technologies could be useful as biomarkers for the early diagnosis, therapeutic targets, and disease response markers. In this article, we discuss recent progress and challenges for applying quantitative proteomics technologies for biomarker discovery in pancreatic cancer.
Chen
Ru
R
GI Division/Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Pan
Sheng
S
Brentnall
Teresa A
TA
Aebersold
Ruedi
R
D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D007150:Immunohistochemistry; D010190:Pancreatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D040901:Proteomics / Q000379:methods*
D014408:Biomarkers, Tumor